TABLE 2.
Treatment and Outcome in the 9 Patients Treated with T Cell Therapy for PML
| Pt | T Cell Therapy | Last FU | |||||
|---|---|---|---|---|---|---|---|
| Delay from PML Diagnosis to T Cell Therapy, mo | Neurological Status at the Time of T Cell Therapy Initiation | Number of Infusions | JC Virus DNA in the CSF After T Cell Therapy, Copies/ml | FU Duration from PML Diagnosis, mo | Patient Status at Last FU | Neurological Status at Last FU, Residual Deficits | |
| 1 | 4.7 | Severe right hemiparesis, aphasia, behavioral changes (mRS 4) | 4 | — | 69.0 | Alive | Severe hemiparesis, aphasia (mRS 4) |
| 2 | 9.9 | Cognitive impairment, left arm segmental sensory ataxia, epilepsy (mRS 2) | 3 | 290 | 27.7 | Alive | No residual deficit (mRS 1) |
| 3 | 3 | Global aphasia, agraphia, alexia, right hemiparesis (mRS 3) | 1 | — | 3.6 | Deceased (PML) | — |
| 4 | 2.6 | Cortical blindness, left sensory deficit (mRS 2) | 3 | — | 4.4 | Deceased (VZV encephalitis) | — |
| 5 | 5 | Mild cognitive impairment, LHH, seizures (mRS 2) | 6 | 1,860 | 19.3 | Alive | Mild cognitive impairment, LHH (mRS 2) |
| 6 | 2 | Vigilance impairment, left LHH, severe left hemiparesis, hypoesthesia and hemineglect (mRS 5) | 2 | — | 5.0 | Deceased (PML) | — |
| 7 | 2 | Dysarthria, cognitive impairment, severe left hemiparesis (mRS 4) | 4 | — | 6.0 | Deceased (PML) | — |
| 8 | 1.3 | Dysarthria, dysphagia, left arm segmental ataxia, severe gait ataxia (mRS 4) | 6 | Negative | 50.3 | Alive | Mild dysarthria and gait ataxia (mRS 2) |
| 9 | 1.1 | Cognitive impairment, aphasia, dysphagia, agraphia, seizures, vigilance impairment, severe left hemiparesis (mRS 4) | 5 | Negative | 12 | Alive | Mild ataxia and tremor (mRS 2) |
CSF = cerebrospinal fluid; FU = follow‐up; LHH = lateral homonymous hemianopia; mRS = modified Rankin Score; PML = progressive multifocal leukoencephalopathy; Pt = patient; VZV = varicella‐zoster virus; — = not applicable.